Sobi publishes its Report for the Fourth Quarter and Full Year 2014
February 19, 2015 02:00 ET
|
Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB (publ) (Sobi) today announced its results for the
fourth quarter and full year 2014. Revenues for the year totalled SEK 2,607 M
(2,177), an increase of 20 per cent....
Xiapex® får EU-godkännande för behandling av Peyronies sjukdom
January 30, 2015 11:15 ET
|
Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum (Sobi) (STO:SOBI) meddelar att EU-kommissionen har
godkänt Xiapex (clostridium histolyticum kollagenas) för behandling av vuxna män
med Peyronies sjukdom med en påtaglig...
Xiapex approved by the EU Commission for the treatment of Peyronie's disease
January 30, 2015 11:15 ET
|
Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB (publ) (Sobi) today announced that the EU Commission
has approved Xiapex® (collagenase clostridium histolyticum) for the treatment of
adult men with Peyronie's disease with...
Sobi exercises opt-in right for Elocta(TM)
November 21, 2014 02:00 ET
|
Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB (publ) (Sobi) (STO: SOBI) announced today that the
company has decided to exercise its opt-in right to take over final development
and commercialisation of Elocta...
Sobi utnyttjar sin option på Elocta(TM)
November 21, 2014 02:00 ET
|
Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB (publ) (Sobi) (STO: SOBI) meddelade idag att
företaget har beslutat utnyttja sin rättighet att slututveckla och
kommersialisera Elocta (rFVIIIFc) i Europa, Nordafrika och...
Biogen Idec and Sobi announce European Medicines Agency validates Elocta(TM) (rFVIIIFc) Marketing Authorisation Application for review
October 31, 2014 16:08 ET
|
Swedish Orphan Biovitrum AB
Biogen Idec (NASDAQ: BIIB) and Swedish Orphan Biovitrum AB (publ) (Sobi) (STO:
SOBI) today announced that the European Medicines Agency (EMA) has validated the
Marketing Authorisation Application...
Europeiska läkemedelsmyndigheten validerar ansökan om marknadsföringstillstånd för Elocta(TM) (rFVIIIFc)
October 31, 2014 16:08 ET
|
Swedish Orphan Biovitrum AB
Biogen Idec (NASDAQ: BIIB) och Swedish Orphan Biovitrum AB (publ) (Sobi) (STO:
SOBI) meddelade idag att den europeiska läkemedelsmyndigheten (EMA) har
validerat ansökan gällande...
Sobi publicerar resultaten för det tredje kvartalet 2014
October 30, 2014 03:00 ET
|
Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB (publ) (Sobi) presenterade idag sitt resultat för
det tredje kvartalet 2014. De totala intäkterna uppgick till 666 MSEK (517), en
ökning med 29 procent jämfört med...
Sobi publishes Report for the Third Quarter 2014
October 30, 2014 03:00 ET
|
Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB (publ) (Sobi) announced today its results for the
third quarter 2014. Revenue totalled SEK 666 M (517), an increase of 29 per cent
with contribution from all areas of the...
Sobis samarbetspartner Biogen Idec ansöker om marknadsgodkännande för Elocta(TM) (rFVIIIFc) i Europa
October 09, 2014 15:00 ET
|
Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB (publ) (Sobi) meddelar idag att Biogen Idec har
lämnat in ansökan till Europeiska läkemedelsmyndigheten EMA om
marknadsgodkännande (Marketing Authorisation Application,...